Recombinant LAG3 (Relatlimab Biosimilar) antibody

Catalog No. ABIN7795123

The Mouse Monoclonal anti-LAG3 (Relatlimab Biosimilar) antibody (ABIN7795123) specifically detects LAG3 (Relatlimab Biosimilar) in FACS and in vivo. The antibody is reactive with Human samples.

Quick Overview for Recombinant LAG3 (Relatlimab Biosimilar) antibody (ABIN7795123)

Target: LAG3 (Relatlimab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This LAG3 (Relatlimab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-LAG3 (Relatlimab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Relatlimab Biosimilar, Human LAG-3 Monoclonal Antibody

Characteristics: What is relatlimab biosimilar research grade? Relatlimab Biosimilar uses the same protein sequences as the therapeutic antibody relatlimab. Relatlimab is a lymphocyte-activation gene 3 (LAG-3)-blocking antibody that is being investigated with other agents in a variety of tumor types. LAG-3 is a cell-surface molecule found on effector T cells and regulatory T cells, and it works to control T cell response, activation, and growth. Preclinical studies suggest that inhibiting LAG-3 could restore effector function of exhausted T cells and could potentially promote an anti-tumor response. LAG-3 is a component of an immune checkpoint pathway that inhibits T-cell activity. Relatlimab, a human IgG4 LAG-3-blocking antibody, restores the effector function of exhausted T cells, reinvigorating T cells to attack cancer. Relatlimab and the anti-PD-1 agent nivolumab modulate potentially synergistic immune checkpoint pathways and can enhance antitumor immune responses. The two-drug combination has a generally manageable safety profile and can trigger durable tumor regressions in patients with melanoma whose disease has progressed after anti-PD-1 monotherapy.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human LAG-3

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for LAG3 (Relatlimab Biosimilar)

Target: LAG3 (Relatlimab Biosimilar)

Alternative Name: Relatlimab Biosimilar

Target Type: Biosimilar